AbCellera Biologics Inc.

NasdaqGS:ABCL Stock Report

Market Cap: US$754.3m

AbCellera Biologics Balance Sheet Health

Financial Health criteria checks 6/6

AbCellera Biologics has a total shareholder equity of $1.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.4B and $301.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$670.36m
EquityUS$1.11b
Total liabilitiesUS$301.51m
Total assetsUS$1.41b

Recent financial health updates

Recent updates

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

Financial Position Analysis

Short Term Liabilities: ABCL's short term assets ($771.6M) exceed its short term liabilities ($70.4M).

Long Term Liabilities: ABCL's short term assets ($771.6M) exceed its long term liabilities ($231.1M).


Debt to Equity History and Analysis

Debt Level: ABCL is debt free.

Reducing Debt: ABCL has no debt compared to 5 years ago when its debt to equity ratio was 47.1%.

Debt Coverage: ABCL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABCL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies